Home › Research › Caregiving
Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia
Gasca-Salas C, Fernández-Rodríguez B, Pineda-Pardo JA, Rodríguez-Rojas R, Obeso I, Hernández-Fernández F, Del Álamo M, Mata D et al.. Nature communications, 2021-02-03
Topic: Brain proteins, microglia and lab models
Plain-language summary
MR-guided focused ultrasound (MRgFUS), in combination with intravenous microbubble administration, has been applied for focal temporary BBB opening in patients with neurodegenerative disorders and brain tumors. MRgFUS could become a therapeutic tool for drug delivery of putative neurorestorative therapies. Treatment for Parkinson's disease with dementia (PDD) is an important unmet need. We initiated a prospective, single-arm, non-randomized, proof-of-concept, safety and feasibility phase I clinical trial (NCT03608553), which is still in progress. The primary outcomes of the study were to demonstrate the safety, feasibility and reversibility of BBB disruption in PDD, targeting the right parieto-occipito-temporal cortex where cortical pathology is foremost in this clinical state. Changes in β-amyloid burden, brain metabolism after treatments and neuropsychological assessments, were analyzed as exploratory measurements. Five patients were recruited from October 2018 until May 2019, and received two treatment sessions separated by 2-3 weeks. The results are set out in a descriptive manner. Overall, this procedure was feasible and reversible with no serious clinical or radiological side effects. We report BBB opening in the parieto-occipito-temporal junction in 8/10 treatments in 5 patients as demonstrated by gadolinium enhancement. In all cases the procedures were uneventful and no side effects were encountered associated with BBB opening. From pre- to post-treatment, mild cognitive improvement was observed, and no major changes were detected in amyloid or fluorodeoxyglucose PET. MRgFUS-BBB opening in PDD is thus safe, reversible, and can be performed repeatedly. This study provides encouragement for the concept of BBB opening for drug delivery to treat dementia in PD and other neurodegenerative disorders.
What this study adds
Evidence grade: High
In this early phase 1 trial of only five patients, opening the blood-brain barrier with focused ultrasound was feasible and reversible with no serious side effects. The study is still in progress and reports descriptive results, so it does not yet show any treatment benefit.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gasca-Salas, C., Fernández-Rodríguez, B., Pineda-Pardo, J. A., Rodríguez-Rojas, R., Obeso, I., Hernández-Fernández, F., et al. (2021). Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia. Nature communications. https://doi.org/10.1038/s41467-021-21022-9
Vancouver
Gasca-Salas C, Fernández-Rodríguez B, Pineda-Pardo JA, Rodríguez-Rojas R, Obeso I, Hernández-Fernández F, et al. Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia. Nature communications. 2021. doi:10.1038/s41467-021-21022-9. PMID: 33536430.
BibTeX
@article{gascasalas2021-33536430,
author = {Gasca-Salas, C. and Fernández-Rodríguez, B. and Pineda-Pardo, J. A. and Rodríguez-Rojas, R. and Obeso, I. and Hernández-Fernández, F. and Del Álamo, M. and Mata, D. and others},
title = {{Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia}},
journal = {Nature communications},
year = {2021},
doi = {10.1038/s41467-021-21022-9},
pmid = {33536430},
url = {https://doi.org/10.1038/s41467-021-21022-9}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The results are set out in a descriptive manner.
- Overall, this procedure was feasible and reversible with no serious clinical or radiological side effects.
- We report BBB opening in the parieto-occipito-temporal junction in 8/10 treatments in 5 patients as demonstrated by gadolinium enhancement.
- In all cases the procedures were uneventful and no side effects were encountered associated with BBB opening.
Why it matters
In this early phase 1 trial of only five patients, opening the blood-brain barrier with focused ultrasound was feasible and reversible with no serious side effects. The study is still in progress and reports descriptive results, so it does not yet show any treatment benefit.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Evidence strengthHigh
How this study scored 60/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature communications) |
| Journal's citation record | 4 / 4 | Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 317 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 45.3 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 4 / 6 | Cited 13.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 3 / 4 | Cited 194 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jose Angel Obeso: h-index 96 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Biomedical Research Networking Center on Neurodegenerative Diseases: institution h-index 420 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33536430) |
| Free to read | 2 / 2 | Free to read |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41467-021-21022-9
- PubMed: 33536430
- Original source →
- Free full text: Nature Communications →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Caregiving from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.